Miles Company Profile

What is the competitive landscape for MILES

MILES has sixteen approved drugs.

There are six US patents protecting MILES drugs.

There are fifty-four patent family members on MILES drugs in twenty-nine countries and one hundred and twenty-three supplementary protection certificates in fourteen countries.

Summary for Miles

International Patents:	54
US Patents:	6
Tradenames:	18
Ingredients:	11
NDAs:	16

Drugs and US Patents for Miles

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Miles	POTASSIUM CHLORIDE	potassium chloride	INJECTABLE;INJECTION	080195-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Milestone Pharms Usa	CARDAMYST	etripamil	SPRAY;NASAL	218571-001	Dec 12, 2025		RX	Yes	Yes
Miles	STERILE WATER IN PLASTIC CONTAINER	sterile water for irrigation	LIQUID;IRRIGATION	018246-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Miles	DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	dextrose; sodium chloride	INJECTABLE;INJECTION	018500-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Miles	LIDOCAINE HYDROCHLORIDE	lidocaine hydrochloride	INJECTABLE;INJECTION	080414-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Miles	LACTATED RINGER'S IN PLASTIC CONTAINER	calcium chloride; potassium chloride; sodium chloride; sodium lactate	INJECTABLE;INJECTION	018417-001	Approved Prior to Jan 1, 1982		DISCN	No	No

International Patents for Miles Drugs

Country	Patent Number	Estimated Expiration
Hong Kong	1140913
Hong Kong	1249417
South Korea	102653347
Lithuania	3283067
South Korea	101541557
Mexico	2017013355

Supplementary Protection Certificates for Miles Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1758590	2017C/063	Belgium		PRODUCT NAME: SEL DE SODIUM D'ACIDE DESOXYCHOLIQUE; AUTHORISATION NUMBER AND DATE: SE/H/1547/01/DC 20170612
1713823	92595	Luxembourg		PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516
1441735	SPC/GB08/020	United Kingdom		PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
1441735	2008/010	Ireland		PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
2957286	132019000000021	Italy		PRODUCT NAME: PATIROMER SORBITEX CALCIUM E QUALSIASI SUO SALE O DERIVATO(VELTASSA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1179, 20170721

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Miles
• Milestone Pharms Usa

Miles Pharmaceuticals Competitive Landscape Analysis: Market Position, Patent Strength, and Generic/Biosimilar Risk

Last updated: July 8, 2026

Miles Pharmaceuticals appears to operate in the branded generics and specialty-branded segment, but no drug-specific scope (active ingredient list, marketed products, FDA records, or patent estates) is provided. Without the underlying product and regulatory identifiers, a complete, accurate competitive landscape analysis at the level required for licensing, litigation, regulatory, and IP decisions cannot be produced.

What is Miles Pharmaceuticals’ market position in US branded generics and specialty segments?

A defensible market-position assessment requires product-level information (active ingredients, dosage forms, NDCs, FDA approvals, and branded/generic status). No such dataset is included.

How strong is the Miles Pharmaceuticals patent estate for its top-selling products?

Patent strength depends on:

• Orange Book listings per NDA/ANDA (expiration dates, patent numbers, and claims types like composition, method-of-use, and formulation)
• Family structure (priority dates, continuations, terminal disclaimers)
• Enforceable status (expiration, invalidation, settlement, or consent judgments) No Orange Book or patent-list data tied to Miles Pharmaceuticals’ products is provided.

Which patents protect Miles products: composition, formulation, or method-of-use?

Without product identifiers, patent claim-type mapping cannot be performed.

When do Miles patents expire and what exclusivity blocks generics?

Exclusivity timelines require NDA approval dates, pediatric exclusivity where applicable, and listed expiration dates for each Orange Book patent. No such data is provided.

What generic entry risks exist for Miles Pharmaceuticals launches?

Generic entry risk is evaluated using:

• Orange Book carveouts and “no generic” exclusivity windows
• Whether potential ANDA filers can design around method-of-use claims
• Known Paragraph IV filings and litigation outcomes No ANDA/Paragraph IV or litigation data tied to Miles products is included.

Which companies are challenging Miles products with Paragraph IV ANDAs?

This requires the ANDA filer list, patent(s) asserted, and court dockets. No data is provided.

What settlements affect generic launch timing for Miles products?

Settlement terms drive launch dates through agreed-stay periods. No settlement dataset is included.

What is the Orange Book status of Miles Pharmaceuticals’ key products?

Orange Book status requires:

• NDA/ANDA numbers
• Listed patents by claim type
• Expiration dates and any unexpired exclusivity No Orange Book listings are supplied.

How does Miles Pharmaceuticals’ competitive landscape compare with its closest branded-generic and specialty peers?

A valid comparison needs:

• Product overlap by therapeutic class
• Market share by active ingredient
• Price and payer mix (where available) No Miles product portfolio or peer-company mapping is included.

What formulations are protected by Miles patents and what manufacturing/IP barriers exist?

Formulation patent scope is assessed through:

• Claims on solid-state forms, particle size, polymorphs, salts/solvates
• Delivery systems (extended release, transdermal, inhalation)
• Manufacturing/process patents (steps, critical parameters) No Miles-specific patent claims are provided.

What patent litigation affects Miles Pharmaceuticals and how do court outcomes change exclusivity?

Litigation assessment requires:

• Case captions, jurisdictions, asserted patents
• Claim construction outcomes and final judgments No litigation references are provided.

What FDA regulatory pathways govern Miles products and how does that affect exclusivity?

Regulatory status requires:

• NDA/ANDA pathway details (505(b)(1), 505(b)(2), 505(j))
• Approval dates, supplements, and labeling changes No FDA pathway information is provided.

What biosimilar or biologics risk exists for Miles Pharmaceuticals?

Biosimilar risk applies only if Miles markets biologics or “biologic-like” products. No product list or biologic status is supplied.

Miles Pharmaceuticals revenue exposure: which products drive growth and which are approaching loss of exclusivity?

Revenue exposure analysis requires:

• Product-level sales and share trends
• Patent cliff mapping to each active ingredient/dosage form No sales or patent-calendar inputs are included.

Key Takeaways

No product-level, regulatory, or patent data for Miles Pharmaceuticals is provided, so a complete and accurate competitive landscape analysis cannot be generated within the required decision-grade specificity.

FAQs

1. What data sources are required to map an FDA Orange Book patent estate to a company’s marketed NDC portfolio?
2. How do method-of-use versus formulation patents affect ANDA design-around strategies?
3. How does pediatric exclusivity extend generic launch timing under Orange Book?
4. What litigation milestones most strongly predict settlement and launch dates for Paragraph IV cases?
5. How do polymorph or particle-size formulation patents change risk for generic solid oral dosage forms?

References

(No sources cited; no drug-specific regulatory or patent data was provided.)